These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 22494521)

  • 1. Asenapine: a clinical review of a second-generation antipsychotic.
    Stoner SC; Pace HA
    Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.
    Chwieduk CM; Scott LJ
    CNS Drugs; 2011 Mar; 25(3):251-67. PubMed ID: 21323396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania.
    Tarazi FI; Shahid M
    Drugs Today (Barc); 2009 Dec; 45(12):865-76. PubMed ID: 20135021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    J Affect Disord; 2010 Nov; 126(3):358-65. PubMed ID: 20537396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia.
    McIntyre RS; Wong R
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):217-20. PubMed ID: 22182459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials.
    Vita A; De Peri L; Siracusano A; Sacchetti E;
    Int Clin Psychopharmacol; 2013 Sep; 28(5):219-27. PubMed ID: 23719049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
    Szegedi A; Calabrese JR; Stet L; Mackle M; Zhao J; Panagides J;
    J Clin Psychopharmacol; 2012 Feb; 32(1):46-55. PubMed ID: 22198448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    Bipolar Disord; 2009 Nov; 11(7):673-86. PubMed ID: 19839993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asenapine.
    Weber J; McCormack PL
    CNS Drugs; 2009 Sep; 23(9):781-92. PubMed ID: 19689168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asenapine review, part II: clinical efficacy, safety and tolerability.
    Citrome L
    Expert Opin Drug Saf; 2014 Jun; 13(6):803-30. PubMed ID: 24793161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asenapine: a review of acute and extension phase data in bipolar disorder.
    McIntyre RS
    CNS Neurosci Ther; 2011 Dec; 17(6):645-8. PubMed ID: 20950326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
    Kane JM; Mackle M; Snow-Adami L; Zhao J; Szegedi A; Panagides J
    J Clin Psychiatry; 2011 Mar; 72(3):349-55. PubMed ID: 21367356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asenapine.
    Meltzer HY; Dritselis A; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Nov; 8(11):843-4. PubMed ID: 19876039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial.
    Findling RL; Landbloom RL; Mackle M; Wu X; Snow-Adami L; Chang K; Durgam S
    Paediatr Drugs; 2016 Oct; 18(5):367-78. PubMed ID: 27461426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders.
    Reyad AA; Mishriky R
    Psychiatr Danub; 2019 Jun; 31(2):157-161. PubMed ID: 31291219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.
    Stepanova E; Grant B; Findling RL
    Paediatr Drugs; 2018 Apr; 20(2):121-134. PubMed ID: 29170943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
    Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.
    Landbloom RL; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
    J Affect Disord; 2016 Jan; 190():103-110. PubMed ID: 26496015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.